# US 2003/0215442 A1 · Methods and compositions for the treatment or prevention of immune disorders using combination therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215442 A1
- Document ID: US20030215442A1
- Status: Published application
- Kind: A1
- Application number: 10/369,300
- Filed: 2003-02-19
- Published: 2003-11-20
- Earliest claimed: 2002-02-19
- Inventors: Christopher C. Fraser; Wayne Hancock
- Web page: https://patentgrep.com/patent/US20030215442A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides methods of suppressing immune disorders such as allograft rejection in a patient by a combination of inhibition of the binding of LIGHT to HVEM and immunosuppressive therapy. Various therapeutic regimens are provided. The present invention further provides kits and pharmaceutical compositions useful in the present methods.

## Claims

### Claim 1

A method of treating or preventing an immune disorder in a patient, comprising administering to the patient (i) an HVEM-LIGHT inhibitor; and (ii) an immunosuppressive agent, in amounts effective for treating or preventing the immune disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the immune disorder is allograft rejection, delayed-type hypersensitivity, graft versus host disease, a drug allergy, atrophic gastrititis, thyroiditis, allergic encephalomyelitis, autoimmune hemolytic anemia, sympathetic ophthalmia, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, inflammatory bowel disease, or myasthenia gravis.

### Claim 3 (depends on 2)

The method of claim 2, wherein the immune disorder is allograft rejection.

### Claim 4 (depends on 3)

The method of claim 3, wherein the allograft is an organ transplant.

### Claim 5 (depends on 4)

The method of claim 4, wherein the organ is a heart, kidney, liver, lung or pancreas.

### Claim 6 (depends on 3)

The method of claim 3, wherein the allograft is a tissue transplant.

### Claim 7 (depends on 6)

The method of claim 6, wherein the tissue is heart valve, endothelial, cornea, eye lens or bone marrow tissue.

### Claim 8 (depends on 3)

The method of claim 3, wherein the allograft is a skin graft.

### Claim 9 (depends on 1, 3)

The method of claim 1 or 3, wherein the immunosuppressive agent is cyclosporine.

### Claim 10 (depends on 1, 3)

The method of claim 1 or 3, wherein the immunosuppressive agent is FK506.

### Claim 11 (depends on 1, 3)

The method of claim 1 or 3, wherein the immunosuppressive agent is a steroid.

### Claim 12 (depends on 11)

The method of claim 11, wherein the steroid is a corticosteroid.

### Claim 13 (depends on 1, 3)

The method of claim 1 or 3, wherein the immunosuppressive agent is rapamycin.

### Claim 14 (depends on 1, 3)

The method of claim 1 or 3, wherein the immunosuppressive agent is an antibody.

### Claim 15 (depends on 1, 3)

The method of claim 1 or 3, wherein the immunosuppressive agent is an antiproliferative agent.

### Claim 16 (depends on 15)

The method of claim 15, wherein the antiproliferative agent is azathioprine or mycophenolate moefitil.

### Claim 17 (depends on 1, 3)

The method of claim 1 or 3, wherein the immunosuppressive agent is prednisone.

### Claim 18 (depends on 1, 3)

The method of claim 1 or 3, wherein the immunosuppressive agent is a purine analog.

### Claim 19 (depends on 18)

The method of claim 18, wherein the purine analog is methotrexate or mercaptopurine.

### Claim 20 (depends on 1, 3)

The method of claim 1 or 3, wherein the HVEM-LIGHT inhibitor and the immunosuppressive agent are administered concurrently.

### Claim 21 (depends on 20)

The method of claim 20, wherein the HVEM-LIGHT inhibitor and the immunosuppressive agent are both administered daily.

### Claim 22 (depends on 1, 3)

The method of claim 1 or 3, wherein the HVEM-LIGHT inhibitor and the immunosuppressive agent are administered successively.

### Claim 23 (depends on 22)

The method of claim 22, wherein the HVEM-LIGHT inhibitor is administered prior to administration of the immunosuppressive agent.

### Claim 24 (depends on 22)

The method of claim 22, wherein the HVEM-LIGHT inhibitor is administered following administration of the immunosuppressive agent.

### Claim 25 (depends on 22)

The method of claim 22, wherein the HVEM-LIGHT inhibitor and the immunosuppressive agent are administered at a 1-day interval.

### Claim 26 (depends on 22)

The method of claim 22, wherein the HVEM-LIGHT inhibitor and the immunosuppressive agent are administered at a 2-day interval.

### Claim 27 (depends on 22)

The method of claim 22, wherein the HVEM-LIGHT inhibitor and the immunosuppressive agent are administered at a 3-day interval.

### Claim 28 (depends on 1, 3)

The method of claim 1 or 3, wherein the HVEM-LIGHT inhibitor is a soluble HVEM polypeptide.

### Claim 29 (depends on 28)

The method of claim 28, wherein the soluble HVEM polypeptide is a fusion protein further comprising an Ig domain.

### Claim 30 (depends on 1, 3)

The method of claim 1 or 3, wherein the HVEM-LIGHT inhibitor is a soluble LIGHT polypeptide.

### Claim 31 (depends on 30)

The method of claim 30, wherein the soluble LIGHT polypeptide is a fusion protein further comprising an Ig domain.

### Claim 32 (depends on 1, 3)

The method of claim 1 or 3, wherein the HVEM-LIGHT inhibitor is not a herpesvirus gD protein, a lymphotoxin-α protein, a lymphotoxin-β receptor protein, or a TR6 receptor protein.

### Claim 33 (depends on 1, 3)

The method of claim 1 or 3, wherein the HVEM-LIGHT inhibitor is an anti-HVEM antibody.

### Claim 34 (depends on 1, 3)

The method of claim 1 or 3, wherein the HVEM-LIGHT inhibitor is an anti-LIGHT antibody.

### Claim 35 (depends on 1, 3)

The method of claim 1 or 3, wherein the HVEM-LIGHT inhibitor is administered in the form of gene therapy.

### Claim 36 (depends on 1, 3)

The method of claim 1 or 3, wherein the amounts of the HVEM-LIGHT inhibitor and immunosuppressive agent are synergistic.

### Claim 37 (depends on 36)

The method of claim 36, wherein the amount of the HVEM-LIGHT inhibitor or immunosuppressive agent, if administered alone, is not effective for treating allograft rejection.

### Claim 38 (depends on 36)

The method of claim 36, wherein the amount of each of the HVEM-LIGHT inhibitor and immunosuppressive agent, if administered alone, is not effective for treating allograft rejection.

### Claim 39 (depends on 1, 3)

The method of claim 1 or 3, wherein the HVEM-LIGHT inhibitor is conjugated to the immunosuppressive agent.

### Claim 40

A pharmaceutical composition comprising:
a. an HVEM-LIGHT inhibitor;
b. an immunosuppressive agent; and
c. a pharmaceutically acceptable carrier;
wherein the HVEM-LIGHT inhibitor and the immunosuppressive agent are present in amounts effective to prevent or treat allograft rejection.

### Claim 41

A kit comprising in one or more containers:
a. HVEM-LIGHT inhibitor;
b. an immunosuppressive agent; and
c. instructions for the use of the HVEM-LIGHT inhibitor and the immunosuppressive agent in the prevention or treatment of allograft rejection.

### Claim 42

An isolated nucleic acid molecule selected from the group consisting of:
a. a nucleic acid molecule having a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO:3 or a complement thereof as determined using the BLAST algorithm;
b. a nucleic acid molecule comprising at least 15 nucleotide residues and having a nucleotide sequence identical to at least 15 consecutive nucleotide residues of residues 1-424 of SEQ ID NO:3 or a complement thereof;
c. a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:4;
d. a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of any of SEQ ID NO:4, wherein the fragment comprises at least 12 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4; and
e. a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:4, wherein the nucleic acid molecule hybridizes under stringent conditions with a nucleic acid molecule consisting of the nucleotide sequence of any of residues 1-424 of SEQ ID NO:3 or a complement thereof.

### Claim 43 (depends on 42)

The isolated nucleic acid molecule of claim 42, which is selected from the group consisting of:
a. a nucleic acid having the nucleotide sequence of SEQ ID NO:3 or a complement thereof; and
b. a nucleic acid molecule which encodes a polypeptide having the amino acid sequence of any of SEQ ID NO:4 or a complement thereof.

### Claim 44 (depends on 44)

The isolated nucleic acid molecule of claim 44, wherein the fragment comprises at least 15 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4.

### Claim 45 (depends on 44)

The isolated nucleic acid molecule of claim 44, wherein the fragment comprises at least 20 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4.

### Claim 46 (depends on 44)

The isolated nucleic acid molecule of claim 44, wherein the fragment comprises at least 30 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4.

### Claim 47 (depends on 44)

The isolated nucleic acid molecule of claim 44, wherein the fragment comprises at least 40 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4.

### Claim 48 (depends on 44)

The isolated nucleic acid molecule of claim 44, wherein the fragment comprises at least 50 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4.

### Claim 49 (depends on 42, 43)

The isolated nucleic acid molecule of claim 42, 43, or 44, further comprising vector nucleic acid sequences.

### Claim 50 (depends on 42, 43)

The isolated nucleic acid molecule of claim 42, 43, or 44, further comprising nucleic acid sequences encoding a heterologous polypeptide.

### Claim 51 (depends on 42, 43)

A host cell which contains the nucleic acid molecule of claim 42, 43, or 44.

### Claim 52 (depends on 51)

The host cell of claim 51 which is a mammalian host cell.

### Claim 53 (depends on 51)

The host cell of claim 51 which is a non-mammalian host cell.

### Claim 54

An isolated polypeptide selected from the group consisting of:
a. a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:4; wherein the fragment comprises at least 12 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4;
b. a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NO:4, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of residues 1-424 of SEQ ID NO:3 or a complement thereof under stringent conditions; and
c. a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to a nucleic acid consisting of residues 1-424 of SEQ ID NO:3 or a complement thereof as determined using the BLAST algorithm.

### Claim 55 (depends on 54)

The isolated polypeptide of claim 54 having the amino acid sequence of SEQ ID NO:4.

### Claim 56 (depends on 54)

The isolated polypeptide of claim 54, wherein the fragment comprises at least 15 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4.

### Claim 57 (depends on 56)

The isolated polypeptide of claim 56, wherein the fragment comprises at least 20 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4.

### Claim 58 (depends on 56)

The isolated polypeptide of claim 56, wherein the fragment comprises at least 30 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4.

### Claim 59 (depends on 56)

The isolated polypeptide of claim 56, wherein the fragment comprises at least 40 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4.

### Claim 60 (depends on 56)

The isolated polypeptide of claim 56, wherein the fragment comprises at least 50 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4.

### Claim 61 (depends on 54)

The isolated polypeptide of claim 54, wherein the amino acid sequence of the polypeptide further comprises heterologous amino acid residues.

### Claim 62 (depends on 54)

An antibody which selectively binds with the polypeptide of claim 54, which antibody does not bind to a polypeptide comprising SEQ ID NO:2.

### Claim 63 (depends on 51)

A method for producing a polypeptide selected from the group consisting of:
a. a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:4; wherein the fragment comprises at least 12 consecutive amino acid residues of residues 1-80 of SEQ ID NO:4;
b. a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NO:4, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of residues 1-424 of SEQ ID NO:3 or a complement thereof under stringent conditions; and
c. a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to a nucleic acid consisting of residues 1-424 of SEQ ID NO:3 or a complement thereof as determine using the BLAST algorithm.
said method comprising culturing the host cell of claim 51 under conditions in which the nucleic acid molecule is expressed.
